Objective:

To update clinical practice guidelines for radiation therapy in pancreatic cancer, incorporating recent evidence and expanding recommendations.

Approach:

• Guideline Update: The updated guideline replaces the 2019 version and includes new evidence from recent studies and randomized trials.
• Dose Escalation: A strong recommendation for radiation dose escalation is introduced, supported by advances in technology such as adaptive radiation therapy.
• Target Volume Expansion: The guideline now recommends routine elective coverage of areas at high risk for microscopic disease, expanding treatment targets.
• Broader Indications: Addresses radiation therapy for isolated locoregional recurrence, reirradiation, oligometastatic disease, and symptom palliation.

Key Findings:

• The updated guideline emphasizes dose escalation and advanced treatment delivery.
• The SMART trial supports the efficacy of ablative doses in improving survival rates.
• Routine elective coverage of high-risk areas is now recommended to reduce locoregional failures.
• The guideline acknowledges emerging treatment options for medically inoperable patients.

Interpretation:

The updated guidelines reflect a shift in the approach to radiation therapy in pancreatic cancer, moving towards more aggressive and comprehensive treatment strategies.

Limitations:

• Evidence for some recommendations, particularly in settings beyond locally advanced disease, is still maturing.
• Further prospective validation is needed for expanded target volumes.

Conclusion:

The updated guidelines indicate that radiation therapy can be a local treatment strategy in pancreatic cancer, complementing systemic therapies when appropriately selected.

Sources:

• ASTRO Guidelines